<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468129</url>
  </required_header>
  <id_info>
    <org_study_id>11UJPAR</org_study_id>
    <nct_id>NCT01468129</nct_id>
  </id_info>
  <brief_title>Cell Saver Use in Bilateral Total Hip Arthroplasty (THA)</brief_title>
  <official_title>A Prospective, Randomized Controlled Trial to Evaluate the Efficacy of Cell Saver to Redue Blood Loss in One-stage Bilateral Total Hip Arthroplasty (THA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy of using cell saver during bilater total hip
      arthroplasty
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date>December 2012</completion_date>
  <primary_completion_date>December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>One-stage Bilateral Total Hip Replacement</condition>
  <arm_group>
    <arm_group_label>Cell Saver</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Cell Saver</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cell Saver</intervention_name>
    <arm_group_label>Cell Saver</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is over 21 years of age

          -  Subject with bilateral degenerative disease of hips who are candidate for one-stage
             bilateral THA

          -  Subject willing and able to provide written informed consent

        Exclusion Criteria:

          -  Subject with significant comorbidities identified by Charleston index of â‰¥ 3

          -  Subject with malignancy

          -  Subject with history of heart disease, myocardial infarction, pulmonary insufficiency,
             pulmonary embolus, documented fat emboli syndrome, adult respiratory distress
             syndrome, documented patent ductus arteriosus or septal defect, chronic renal failure
             and/or acute hepatic failure or chirhosis

          -  Subjects with hematologic disorders such as anemia (Hb &lt; 10 g/dL) and sickle cell
             disease, acquired or congenital coagulopathies, acquired or congenital bleeding
             disorders,

          -  Subject who received anticoagulant such as aspirin or Warfarin (Coumadin) or
             antiplatelet agents such as clopidogrel (Plavix) within 7 days of surgery

          -  Subject who received hemostatic agents such as tranexamic acid and aprotinin

          -  Subjects utilizing acute normovolumic haemodilution

          -  Subject is not permitted to remain without his/her anti-coagulant regimen (eg Plavix)
             for 48 hours postoperatively

          -  Subject is known to be pregnant.

          -  Subject has erythropoietin agonist/stimulating agent within 90 days prior to surgery.

          -  Presence of contaminants such as urine, fat, bowel contents, and most importantly
             infection in the operative field

          -  Presence of vasoactive drugs such as papaverine in the operative field
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tiffany Morrison, MS</last_name>
    <email>tiffany.morrison@rothmaninstitute.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javad Parvizi, MD, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Hozack, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Purtill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Austin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

